

研究方向

1. 肝硬化之心臟、胃食道靜脈瘤及腹水等門脈高壓症相關之併發症。
2. 脂肪肝併肝纖維化時，肝內阻力增加後所造成臨床併發症的治療提供一個新的方向。
3. 肝硬化時肝內氧化壓力增加及異常血管新生的病理機轉及未來治療契機之研究。

獲獎紀錄

- 1 財團法人肝病防治學術基金會肝病防治優秀論文獎(2011)
2. 台北榮民總醫院優良醫師「醫師學術論文獎」(2011&2012)
3. 行政院國家科學委員會吳大猷先生紀念獎(2012)
4. 中研院年輕學者研究著作獎(2013)

代表著作

1. **Yang YY**, Lin HC, Huang YT, Lee TY, Hou MC, Lee FY, Ren-Shyan Liu, FY Chang, Lee SD. Effect of one-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. **J Hepatol** 2002;36:600-6.
2. **Yang YY**, Lin HC, Huang YT, Hou MC, Lee FY, Chang FY, Lee SD. Inhibition of glucagon improves splanchnic hyporesponse to terlipressin in cirrhotic rats with blood retention in the gastric lumen. **J Hepatol** 2005;42:652-8.
3. **Yang YY**, Liu HQ, Nam SW, Kunos G, Lee SS. Mechanisms of TNF α -induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNF α and endocannabinoids. **J Hepatol** 2010;53(2):298-306.
4. **Yang YY**, Lin HC, Lee WP, Chu CJ, Lin MW, Lee FY, Hou MC, Jap JS, Lee SD. Association of the G-protein and alpha-2 adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of effects of diuretics in cirrhotic patients with refractory ascites: a randomized clinical trial. **Gut** 2010;59:1545-53.
5. Lin HC, **Yang YY**, Tsai TH, Huang CM, Huang YT, Lee FY, et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension **J Hepatol** 2011;45:1145-53 (co-first author).
6. **Yang YY**, Tsai TH, Huang YT, Lee TY, Chan CC, Lee KC, Lin HC. Hepatic Endothelin-1 and Endocannabinoids-Dependent Effects of Hyperleptinaemia in Nonalcoholic Steatohepatitis-Cirrhotic Rats. **Hepatology** 2012; 55: 1540-50.
7. **YY Yang**, Hsieh SL, Lee P, Yeh Y, Lee KC, Hsieh YC, Wang YW, Lee TY, Huang YH, Chan CC, Lin HC. Long-term cannabinoid type 2 receptor agonist therapy decreases Bacterial Translocation In Rats with cirrhosis and ascites. **J Hepatol** 2014 : 61(5):1004-1013.
8. **Yang YY**, Lee PC, Huang YT, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Lee TY, Lin HC. Involvement of the HIF-1 α and Wnt/ β -catenin pathways on the protective effects of losartan on fatty liver graft with ischemia/reperfusion injury. **Clin Sci (Lond)** 2014; 126: 163-174.
9. **Yang YY**, Liu RS, Lee PC, Yeh YC, Huang YT, Lee WP, Lee KC, Hsieh YC, Lee FY, Tan TW, Lin HC. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. **Liver Int** 2014;34: 521-34.
10. Lin HC, Huang YT, **Yang YY**, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS. Beneficial effects of dual VEGFR/FGFR inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. **J Gastroenterol Hepatol** 2014;29:1073-82 (co-first author).
11. PC Lee, **YY Yang**, MC Hou, CS Huang, KC Lee, YW Wang, YC Hsieh, YH Huang, CJ Chu, HC Lin. Benzodiazepine-Associated Hepatic Encephalopathy Significantly Increased Healthcare

Utilization and Medical Cost of Chinese Cirrhotic Patients: 7-years Experiences. *Diges Dis Sci* 2014;59(7):1603-16 (corresponding author).

12. Lee PC, **Yang YY**, Lee WP, Lee KC, Hsieh YC, Lee TY, Lin H. Vitamin D₃ treatment has comparative portal hypotensive effects as propranolol by decreasing intrahepatic resistance in cirrhotic rats. **J Gastroenterol Hepatol** 2014 (accepted) (**corresponding author**).
13. Lee PC, **Yang YY**, Huang CS, Hsieh SL, Lee KC, Hsieh YC, Lee TY, Lin HC. Concomitant inhibition of oxidative stress and angiogenesis by chronic hydrogen-rich saline and N-acetylcysteine treatments improves systemic, splanchnic and hepatic hemodynamics of cirrhotic rats. **Hep Res** 2014 (accepted) (**corresponding author**).